Compare Adaptive Biotechnologies Corp (ADPT) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.05 (market cap $3.33B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.63. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Vanguard Sht-Term Inflation-Protected Sec Idx ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | VTIP | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | — |
52-Week High | $22.37 | $50.75 |
52-Week Low | $10.24 | $49.39 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
VTIP (Vanguard Short-Term Inflation-Protected Securities ETF) trades at $49.64 with minimal daily movement (+0.12%). The technical picture shows conflicting signals with moving averages indicating bearish pressure while oscillators suggest potential oversold conditions. Recent news highlights VTIP's role as an inflation hedge, with multiple institutional investors increasing positions. The ETF focuses on short-term Treasury Inflation-Protected Securities, designed to protect against rising consumer prices.
VTIP offers investors exposure to inflation-protected government bonds with lower duration risk than longer-term TIPS funds. Current market conditions favor inflation-hedging assets, though the fund faces risks from potential Fed policy shifts and interest rate volatility. The ETF's structure provides built-in CPI adjustment, making it relevant in the current inflationary environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
